Pharmaxis

Previous name for @SyntaraTX - biotech leaders in drug discovery for diseases linked to fibrosis and inflammation.

[Syntara Limited @SyntaraTx]

Syntara (#ASX: $SNT) was featured this week at Twilight Briefings where Gary Phillips provided updates on clinical trials targeting #myelofibrosis, IRBD and #ParkinsonsDisease, skin scarring and Myelodysplastic Syndrome. View the investor presentation: https://t.co/Lqps6QWvar

[Syntara Limited @SyntaraTx]

Following news of Syntara's (#ASX: $SNT) new Phase 2 clinical study targeting #MyelodysplasticSyndrome, CEO Gary Phillips was featured on @proactive_au to discuss the trials that will aim to reduce dependence on transfusions among #bloodcancer patients: https://t.co/CtW493NZeM

[Syntara Limited @SyntaraTx]

In partnership with @Uni_Newcastle and @ALLGtrials, Syntara (#ASX: $SNT) has announced a Phase 2 trial evaluating SNT-5505 in combination with chemotherapy in patients with risk of myelodysplastic syndrome. It follows a $0.83m grant by the MRFF. More: https://t.co/zM5WzKF9ap

[Syntara Limited @SyntaraTx]

Syntara (#ASX: $SNT) is pleased to release its first quarterly report since divesting the mannitol business unit, providing a robust financial foundation to focus on the 3 Phase 1c/2 clinical studies targeting unmet needs. View the full report: https://t.co/Ycvg9pcPJf

[Syntara Limited @SyntaraTx]

Syntara (#ASX: $SNT) is delighted to welcome new and existing investors that have committed $10m towards SNT drug development, including the attractive commercial opportunity for SNT-5505 as a #myelofibrosis treatment. CEO Gary Phillips discusses more: https://t.co/XKY0ED5MPf

[Syntara Limited @SyntaraTx]

The first patients in the final cohort of Syntara (#ASX: $SNT)'s Phase 2 trials to treat #myelofibrosis, have commenced dosing. This cohort is undergoing a combination treatment of SNT-5505 with the market leading JAK inhibitor, #ruxolitinib. Read more: https://t.co/zd6HEPTQVr

[Pharmaxis @Pharmaxis]

At today’s AGM, @Syntara's Board and management set out the value opportunities as the newly named company completes a restructure and advances its new drug assets in blood cancer, skin scarring and neurodegeneration.

[Pharmaxis @Pharmaxis]

At today’s AGM, @Syntara's Board and management set out the value opportunities as the newly named company completes a restructure and advances its new drug assets in blood cancer, skin scarring and neurodegeneration.

[Syntara Limited @SyntaraTx]

The first patient has been dosed in our Phase 2 study for isolated Rapid Eye Movement Sleep Behavior Disorder (#iRBD), a precursor of #Parkinsonsdisease. The trial is primarily funded by a program founded by @ParkinsonsUK. View more: https://t.co/DUpztzJZ0y

[Syntara Limited @SyntaraTx]

As Pharmaxis prepares for its transformation to Syntara, a #biotech focused on clinical stage drug development, CEO Gary Phillips updated investors on the potential for 5 phase 1c/2 studies to deliver clinical data in a 9 month window. View more: https://t.co/XPqIqDbgXX

[Syntara Limited @SyntaraTx]

Dr Boreham’s Crucible: Investors have been holding their breath for Pharmaxis’ rebirth. Time to exhale? https://t.co/amJS00dexq

[Syntara Limited @SyntaraTx]

$PXS Pharmaxis finalises sale of MBU to Arna Pharma; shifts focus to blood-related cancer treatments https://t.co/PbDVH0Ovgd @Pharmaxis $PMXSF #PXS #PMXSF

[Syntara Limited @SyntaraTx]

We are pleased to release a new Investor Presentation, the first on our Syntara branding, subject to shareholder approval. The presentation outlines Syntara as a specialist drug development company prioritising haematological malignancies. View here: https://t.co/p8OUtPwEcK